Murine Models of Graft-versus-Host Disease and Graft-versus-Tumor Effect

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 176-187

  Korngold, Robert ^a   Friedman, Thea M ^b  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b Lymphoma Division   (United States)

Author keywords

Anti mHA GVHD features; Donor marrow plus donor CD4+ cells; Effects of adding CD4+ cells; Graft versus host disease (GVHD); GVHD in nonirradiated hosts; GVHD to H 2 class II antigens; GVHD to mHAs; Murine models of Graft versus Host Disease and Graft versus Tumor Effect; Regulatory cells and GVHD

Indexed keywords

EID: 84858332804     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch14     Document Type: Chapter

References (139)

1. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999; 5: 347-56.
2. Ferrara J, Deeg JH, Burakoff SJ, editors. Graftvs.- Host Disease. New York: Marcel Dekker; 1997.
3. Korngold R. Biology of graft-vs.-host disease. Am J Ped Hematol/Oncol 1993; 15: 18-27.
4. Sprent J, Webb SR. Function and specificity of T-cell subsets in the mouse. Adv Immunol 1987; 41: 39-133.
5. Hedrick SM, Eidelman FJ. T lymphocyte antigen receptors. In: Paul WE, editor. Fundamental Immunology, 3rd edn. New York: Raven Press; 1993. pp. 383-420.
6. Shevach EM. Accessory molecules. In: Paul WE, editor. Fundamental Immunology, 3rd edn. New York: Raven Press; 1993. pp. 531-76.
7. Carbone FR, Bevan MJ. Major histocompatibility complex control of T-cell recognition. In: Paul WE, editor. Fundamental Immunology, 2nd edn. New York: Raven Press; 1989. pp. 541-70.
8. Sprent J. T lymphocytes and the thymus. In: Paul WE, editor. Fundamental Immunology, 3rd edn. New York: Raven Press; 1993. pp. 75-110.
9. von Boehmer H. Developmental biology of T cells in T-cell receptor transgenic mice. Annu Rev Immunol 1990; 8: 531-56.
10. Whitelegg A, Barber LD. The structural basis of T-cell allorecognition. Tissue Antigens 2004: 63: 101-8.
11. Sprent J, Schaefer M, Lo D, Korngold R. Properties of purified T-cell subsets. II. In vivo responses to class I vs. class II H2 differences. J Exp Med 1986; 163: 998-1011.
12. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-15.
13. Matte CC, Liu J, Cormier J et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10: 987-92.
14. Teshima T, Ordemann R, Reddy P et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575-81.
15. Korngold R, Sprent J. Features of T cells causing H2-restricted lethal graft-versus-host disease across minor histocompatibility barriers. J Exp Med 1982; 155: 872-83.
16. Jones SC, Murphy GF, Friedman TM, Korngold R. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. J Clin Invest 2003; 112: 1880-6.
17. Sprent J, Korngold R. A comparison of lethal graft-versus-host disease to minor-versus-major differences in mice: implications for marrow transplantation in man. Prog Immunol 1983; 5: 1461-75.
18. Bennett M. Biology and genetics of hybrid resistance. Adv Immunol 1987; 41: 333-445.
19. Murphy WJ, Kumar V, Bennett M. Rejection of bone marrow allografts by mice with severe combined immunodeficiency (SCID): evidence that natural killer (NK) cells can mediate the specificity of marrow graft rejection. J Exp Med 1987; 165: 1212-17.
20. Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient hemopoietic cells by irradiated MHC-matched mice. Nature 1991; 349: 329-31.
21. Jones M, Komatsu M, Levy RB. Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex-matched bone marrow allografts. Biol Blood Marrow Transplant 2000; 6: 456-64.
22. Moller G, editor. Elimination of allogeneic lymphoid cells. Immunol Rev 1983; 73: 1-126.
23. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 2006; 214: 202-18.
24. Vallera DA, Soderling CCB, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants. J Immunol 1982; 128: 871-5.
25. Korngold R, Sprent J. Surface markers of T cells causing lethal graft-versus-host disease to class I vs. class II H2 differences. J Immunol 1985; 135: 3004-10.
26. Korngold R, Sprent J. Purified T-cell subsets and lethal graft-versus-host disease in mice. In: Gale RP, Champlin R, editors. Progress in Bone Marrow Transplantation. New York: Liss; 1987. pp. 213-18.
27. Cobbold S, Martin G, Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. Transplantation 1986; 42: 239-47.
28. Piguet P-F. GVHR elicited by products of class I or class II loci of the MHC: analysis of the response of mouse T lymphocytes to products of class I and class II loci of the MHC in correlation with GVHR-induced mortality, medullary aplasia, and enteropathy. J Immunol 1985; 135: 1637-43.
29. Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmunelike syndrome. J Immunol 1993; 151: 5726-41.
30. Vallera DA, Taylor PA, Panoskaltsis-Mortari A, Blazar BR. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti- CD3F(ab')2-ricin toxin A chain immunotoxin. Blood 1995; 86: 4367-75.
31. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graftversus- host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960-7.
32. + cells in vitro and in vivo. Immunol Rev 1986; 91: 195-218.
33. + cells in anti-class II H2 differences. J Immunol 1990; 144: 2946-54.
34. Guy-Grand D, Vassalli P. Gut injury in mouse graft-versus-host reactions. J Clin Invest 1986; 77: 1584-95.
35. Mowat AM, Sprent J. Induction of intestinal graftversus- host reactions across mutant major histocompatibility antigens by T lymphocyte subsets in mice. Transplantation 1989; 47: 857-63.
36. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166: 1280-9.
37. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factoralpha in graft-versus-host disease and graftversus- leukemia responses. Biol Blood Marrow Transplant 2003; 9: 292-303.
38. Vossen JM, Heidt PJ. Gnotobiotic measures for prevention of acute graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K, editors. Graft-Versus-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker; 1990. pp. 403-13.
39. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996; 184: 387-96.
40. + T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 2000; 12: 1145-55.
41. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-9.
42. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-99.
43. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-6.
44. Jones SC, Murphy GF, Korngold R. Posthematopoietic cell transplantation control of graftversus- host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 2003; 9: 243-56.
45. Johnson BD, Becker EE, LaBelle JL, Truitt RL. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. J Immunol 1999; 163: 6479-87.
46. Edinger M, Hoffmann P, Ermann J et al. CD4+CD25+ regulatory T cells preserve graftversus- tumor activity while inhibiting graftversus- host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-50.
47. Xia G, Truitt RL, Johnson BD. Graft-versusleukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by hosttype antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006; 4: 397-407.
48. Trenado A, Charlotte F, Fisson S et al. Recipienttype specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graftversus- host disease while maintaining graftversus- leukemia. J Clin Invest 2003; 112: 1688-96.
49. Steiner D, Brunicki N, Blazar BR, Bachar-Lustig E, Reisner Y. Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells. Exp Hematol 2006; 34: 66-71.
50. Taylor PA, Panoskaltsis-Mortari A, Swedin JM et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004; 104: 3804-12.
51. Ermann J, Hoffmann P, Edinger M et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005; 105: 2220-6.
52. Nguyen VH, Shashidhar S, Chang DS et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008; 111: 945-53.
53. Giorgini A, Noble A. Blockade of chronic graftversus- host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts. J Leukoc Biol 2007; 82: 1053-61.
54. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007; 110: 3804-13.
55. Zeiser R, Nguyen VH, Beilhack A et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-9.
56. Coenen JJ, Koenen HJ, van Rijssen E et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007; 39: 537-45.
57. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001; 97: 2923-31.
58. Margalit M, Ilan Y, Ohana M et al. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes. Bone Marrow Transplant 2005; 35: 191-7.
59. Hashimoto D, Asakura S, Miyake S et al. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 2005; 174: 551-6.
60. Pillai AB, George TI, Dutt S, Teo P, Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007; 178: 6242-51.
61. Ilan Y, Ohana M, Pappo O et al. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity. Transplantation 2007; 83: 458-67.
62. Nathenson SG, Geliebter J, Pfaffenbach GM, Zeff RA. Murine major histocompatibility complex class-I mutants. Molecular analysis and structure-function implications. Ann Rev Immunol 1986; 4: 471-502.
63. + cells in class Idifferent hosts. J Exp Med 1988; 167: 556-9.
64. Simonsen M. Graft-versus-host reactions. Their natural history and applicability as tools of research. Progr Allergy 1962; 6: 349-467.
65. Rolink AG, Pals ST, Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H2K and/or I-A. J Exp Med 1983; 157: 755-71.
66. Gleichmann E, Pals ST, Rolink AG, Radaszkiewicz T, Gleichmann H. Graft-versus-host reactions. Clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 1984; 5: 324-32.
67. Rolink AG, Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-vs.- host disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med 1983; 158: 546-58.
68. Rolink AG, Radaszkiewicz T, Pals ST, van der Meer WGJ, Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-vs.- host disease. I. Alloreactive suppressor cells rather than killer T cells appear to be the decisive cells in lethal graft-vs.-host disease. J Exp Med 1982; 155: 1501-22.
69. van Elven EH, Rolink AG, van der Veen F, Gleichmann E. Capacity of genetically different T lymphocytes to induce lethal graft-versus-host disease correlates with their capacity to generate suppression but not with their capacity to generate anti-F1 killer cells. A non-H2 locus determines the inability to induce lethal graft-versus-host disease. J Exp Med 1981; 153: 1474-88.
70. Via CS, Sharrow SO, Shearer GM. Role of cytotoxic T lymphocytes in the prevention of lupuslike disease occurring in a murine model of graft-vs.-host disease. J Exp Med 1987; 139: 1840-9.
71. Wang W, Meadows LR, den Haan JM et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269: 1588-90.
72. den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998; 279: 1054-7.
73. Goulmy E. Minor histocompatibility antigens: from T cell recognition to peptide identification. Hum Immunol 1997; 54: 8-14.
74. Korngold R, Sprent J. Lethal graft-versus-host disease after bone-marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978; 148: 1687-98.
75. Hamilton BL, Bevan MJ, Parkman R. Antirecipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graftversus- host disease due to minor histocompatibility antigens. J Immunol 1981; 126: 621-5.
76. Korngold R, Leighton C, Mobraaten LE, Berger MA. Inter-strain graft-versus-host disease T cell responses to immunodominant minor histocompatibility antigens. Biol Blood Marrow Transplant 1997; 3: 57-64.
77. Blazar BR, Roopenian DC, Taylor PA, Christianson GJ, Panoskaltsis-Mortari A, Vallera DA. Lack of GVHD across classical, single minor histocompatibility (miH) locus barriers in mice. Transplantation 1996; 61: 619-24.
78. Perreault C, Jutras J, Roy DC, Filep JG, Brochu S. Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versushost disease. J Clin Invest 1996; 98: 622-8.
79. + T cell responses to minor histocompatibility antigens involved in graft-versus-host disease. J Immunol 1998; 161: 41-8.
80. DiRienzo CG, Murphy GF, Jones SC, Korngold R, Friedman TM. T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12: 818-27.
81. + T cell receptor Vb repertoire involved in graftversus- host disease responses to minor histocompatibility antigens. J Immunol 1997; 159: 77-85.
82. Howell CD, Li J, Roper E, Kotzin BL. Biased liver T cell receptor Vb repertoire in a murine graft-versus-host disease model. J Immunol 1995; 155: 2350-8.
83. Brochu S, Baron C, Hetu F, Roy DC, Perreault C. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras. J Immunol 1995; 155: 5104-14.
84. Perreault C, Roy DC, Fortin C. Immunodominant minor histocompatibility antigens: the major ones. Immunol Today 1998; 19: 69-74.
85. Korngold R, Wettstein PJ. Immunodominance in the graft-vs-host disease T-cell response to minor histocompatibility antigen. J Immunol 1990; 145: 4079-88.
86. Nevala WK, Wettstein PJ. H4 and CTT-2 minor histocompatibility antigens: concordant genetic linkage and migration in two-dimensional peptide separation. Immunogenetics 1996; 44: 400-4.
87. Malarkannan S, Shih PP, Eden PA et al. The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol 1998; 161: 3501-9.
88. Malarkannan S, Horng T, Eden PA et al. Differences that matter: major cytotoxic T cellstimulating minor histocompatibility antigens. Immunity 2000; 3: 333-44.
89. Wettstein PJ. Immunodominance in the T-cell response to multiple non-H2 histocompatibility antigens. II. Observation of a hierarchy among dominant antigens. Immunogenetics 1986; 24: 24-31.
90. + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 1987; 165: 1522-64.
91. Korngold R, Sprent J. Lethal GVHD across minor histocompatibility barriers: nature of the effector cells and role of the H2 complex. Immunol Rev 1983; 71: 5-29.
92. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol 1983; 77: 1-12.
93. Ferrara J, Guillen FJ, Sleckman B, Burakoff SJ, Murphy GF. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model. Histologic analysis and correlation to clinical disease. J Invest Dermatol 1986; 123: 401-6.
94. Rappaport H, Khalil A, Halle-Pannenko O, Pritchard L, Dantcher D, Mathe G. Histopathologic sequence of events in adult mice undergoing lethal graft-vs-host reaction developed across H2 and/or non H2 histocompatibility barriers. Am J Pathol 1979; 96: 121-43.
95. Charley MR, Bangert JL, Hamilton BL, Gilliam JN, Sontheimer RD. Murine graft-versus-host skin disease. A chronologic and quantitative analysis of two histologic patterns. J Invest Dermatol 1983; 81: 412-17.
96. Murphy GF, Whitaker D, Sprent J, Korngold R. Characterization of target injury of murine acute graft-versus-host disease directed to multiple minor histocompatibility antigens elicited by either CD4+ or CD8+ effector cells. Am J Path 1991; 138: 983-90.
97. + T-cell responses. Bone Marrow Transplant 1992; 9: 355-64.
98. Berger M, Wettstein PJ, Korngold R. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 1994; 57: 1095-102.
99. Kwon B, Moon CH, Kang S, Seo SK, Kwon BS. 4-1BB: still in the midst of darkness. Mol Cells 2000; 10: 119-26.
100. Hamilton BL. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol 1987; 139: 2511-15.
101. + T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate. Biol Blood Marrow Transplant 2001; 7: 2-13.
102. Jones SC, Friedman TM, Murphy GF, Korngold R. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versushost disease directed to multiple minor histocompatibility antigens. Biol Blood Marrow Transplant 2004; 10: 91-105.
103. DiRienzo CG, Murphy GF, Friedman TM, Korngold R. T-cell receptor V(alpha) usage by effector CD4+Vbeta11+ T cells mediating graftversus- host disease directed to minor histocompatibility antigens. Biol Blood Marrow Transplant 2007; 13: 265-76.
104. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991; 8: 51-8.
105. Palathumpat V, Dejbakhsh-Jones S, Strober S. The role of purified CD8+ T cells in graft-versusleukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 1995; 60: 355-61.
106. Zhang C, Lou J, Li N et al. Donor CD8+ T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody. J Immunol 2007; 178: 838-50.
107. Fowler DH, Gress RE. CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection. Vox Sang 1998; 74(Suppl 2): 331-40.
108. Suzuki Y, Adachi Y, Minamino K et al. A new strategy for treatment of malignant tumor: intrabone marrow-bone marrow transplantation plus CD4-donor lymphocyte infusion. Stem Cells 2005; 23: 365-70.
109. Johnson BD, Becker EE, Truitt RL. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant 1999; 5: 123-32.
110. Anderson BE, McNiff J, Yan J et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003; 112: 101-8.
111. Giver CR, Montes RO, Mittelstaedt S et al. Ex vivo fludarabine exposure inhibits graft-versushost activity of allogeneic T cells while preserving graft-versus-leukemia effects. Biol Blood Marrow Transplant 2003; 9: 616-32.
112. Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood 2004; 103: 1534-41.
113. Zhang Y, Joe G, Zhu J et al. Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood 2004; 103: 3970-8.
114. Ji YH, Weiss L, Zeira M et al. Allogeneic cellmediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses. Bone Marrow Transplant 2003; 32: 495-504.
115. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest 1998; 102: 473-82.
116. O'Shaughnessy MJ, Chen ZM, Gramaglia I et al. Elevation of intracellular cyclic AMP in alloreactive CD4(+) T cells induces alloantigen-specific tolerance that can prevent GVHD lethality in vivo. Biol Blood Marrow Transplant 2007; 13: 530-42.
117. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540-9.
118. Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graftversus- host disease. J Immunol 1996; 157: 4811-21.
119. Hsieh MH, Varadi G, Flomenberg N, Korngold R. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graftversus- host disease risk. Biol Blood Marrow Transplant 2002; 8: 303-15.
120. Schmaltz C, Alpdogan O, Horndasch KJ et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versushost disease and graft-versus-leukemia effect. Blood 2001; 97: 2886-95.
121. Sykes M, Harty MW, Szot GL, Pearson DA. Interleukin-2 inhibits graft-versus-host diseasepromoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560-9.
122. Krijanovski OI, Hill GR, Cooke KR et al. Keratinocyte growth factor separates graft-versusleukemia effects from graft-versus-host disease. Blood 1999; 94: 825-31.
123. Hill GR, Teshima T, Gerbitz A et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104: 459-67.
124. Teshima T, Hill GR, Pan L et al. IL-11 separates graft-versus-leukemia effects from graft-versushost disease after bone marrow transplantation. J Clin Invest 1999; 104: 317-25.
125. Reddy P, Teshima T, Hildebrandt G et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2003; 101: 2877-85.
126. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factoralpha in graft-versus-host disease and graftversus- leukemia responses. Biol Blood Marrow Transplant 2003; 9: 292-303.
127. Durakovic N, Radojcic V, Powell J, Luznik L. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versusleukemia reactivity. Transplantation 2007; 83: 631-40.
128. Pelot MR, Pearson DA, Swenson K et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide- based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133-43.
129. Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 2003; 102: 2300-7.
130. Anderson LD Jr, Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 2000; 95: 2426-33.
131. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graftversus- host disease. Nat Med 2001; 7: 789-94.
132. Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, Perreault C. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 2005; 11: 1222-9.
133. + T cells provides graftversus- leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 187-96.
134. Kernan NA. T-cell depletion for the prevention of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplantation, 2nd edn. Malden, MA: Blackwell Science; 1999. pp. 186-96.
135. Murphy GF, Sueki H, Teuscher C, Whitaker D, Korngold R. Role of mast cells in early epithelial target cell injury in experimental acute graftversus- host disease. J Invest Dermatol 1994; 102: 451-61.
136. Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF. Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versus-host disease. J Invest Dermatol 1996; 107: 377-83.
137. Murphy GF, Lavker RM, Whitaker D, Korngold R. Cytotoxic folliculitis in acute graft-versus-host disease. Evidence of follicular stem cell injury and recovery. J Cutan Pathol 1991; 18: 309-14.
138. Sale GE, Beauchamp M. The parafollicular hair bulge in human GVHD. A stem cell rich primary target. Bone Marrow Transplant 1993; 11: 223-5.
139. Whitaker-Menezes D, Jones SC, Friedman TM, Korngold R, Murphy GF. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression. Biol Blood Marrow Transplant 2003; 9: 559-70.